Open access
Jul 2026
An Open-Label Feasibility Study of Remdesivir in Long COVID: Results from the ERASE LC Trial
Analysis of secondary outcomes suggests therapeutic promise, but rigorous evaluation in large-scale randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in people with Long COVID (LC).
M. Faghy, J. Chynoweth, A. Barnett et al.
· medRxiv · 0 citations